← Drug database

Alimta (pemetrexed)

Region
🇪🇺 EU
Active substance
pemetrexed
Company
Eli Lilly Nederland B.V.
Status
Authorised
Therapeutic area
Mesothelioma; Carcinoma, Non-Small-Cell Lung
EU approval
Mon 20 Sep 2004
Application
EMEA/H/C/000564
ATC
L01BA04
Official record
www.ema.europa.eu

Indication

Malignant pleural mesothelioma Alimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma. Non-small-cell lung cancer Alimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Alimta

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.